The Department of Justice announced on June 26, 2026, that its 2026 National Health Care Fraud Takedown resulted in charges against 455 defendants across 56 federal districts for alleged participation in health care fraud and opioid diversion schemes totaling more than $6.5 billion in false or fraudulent claims [1]. Among those charged, 90 are licensed medical professionals [1]. The operation marks the largest coordinated health care fraud enforcement action in DOJ history by the measure of state-level participation [1].
The charges span alleged fraudulent billing to Medicare, Medicaid, and other federal health programs, as well as opioid-related offenses involving prescription distribution outside legitimate medical practice [1]. The takedown engaged 50 state Medicaid Fraud Control Units, a record for any single DOJ enforcement operation [1]. Federal partners included the DOJ National Fraud Enforcement Division, the Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services, and the FBI [1]. The breadth of the operation reflects the federal government's continued reliance on parallel criminal and administrative enforcement to address systematic billing fraud, a practice DOJ has pursued through annual takedown cycles since 2007.
The June 26 announcement represents the charging phase of the operation. Individual cases will proceed in their respective federal districts, with prosecutors in each jurisdiction responsible for arraignments, detention hearings, and pretrial motions on their own timelines. The inclusion of licensed medical professionals as defendants raises the likelihood that some cases will involve parallel proceedings before state medical licensing boards, which routinely act on criminal charges implicating clinical conduct. HHS-OIG retains independent authority to impose administrative exclusions from federal health programs, a sanction that operates separately from any criminal conviction and can precede a final judgment [1].
Given the scale of charged conduct and the number of jurisdictions involved, the case load will resolve over months or years rather than weeks. Defendants facing the most serious fraud allegations, particularly those tied to large-scale billing operations, may draw early plea negotiations as prosecutors seek to establish facts useful in related prosecutions. The opioid-specific charges, where sentencing exposure under federal guidelines is significant, are likely to produce their own distinct resolution track. DOJ has not announced a civil recovery target, but parallel False Claims Act actions by the Civil Division or private relators remain a standard follow-on tool in takedowns of this scale.